527 related articles for article (PubMed ID: 32917214)
1. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook.
Horvath L; Thienpont B; Zhao L; Wolf D; Pircher A
Mol Cancer; 2020 Sep; 19(1):141. PubMed ID: 32917214
[TBL] [Abstract][Full Text] [Related]
2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
3. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.
Zhang S; Bai X; Shan F
Int Immunopharmacol; 2020 Mar; 80():106247. PubMed ID: 32007710
[TBL] [Abstract][Full Text] [Related]
4. Immune profiling reveals the diverse nature of the immune response in NSCLC and reveals signaling pathways that may influence the anti-tumor immune response.
Hamm CA; Pry K; Lu J; Bacus S
Exp Mol Pathol; 2019 Aug; 109():1-15. PubMed ID: 30953647
[TBL] [Abstract][Full Text] [Related]
5. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F
J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
7. PD-L1
Zhang L; Zhang X; Liu Y; Zhang T; Wang Z; Gu M; Li Y; Wang DD; Li W; Lin PP
Cancer Lett; 2020 Jan; 469():355-366. PubMed ID: 31678168
[TBL] [Abstract][Full Text] [Related]
8. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer.
Schalper KA; Carvajal-Hausdorf D; McLaughlin J; Altan M; Velcheti V; Gaule P; Sanmamed MF; Chen L; Herbst RS; Rimm DL
Clin Cancer Res; 2017 Jan; 23(2):370-378. PubMed ID: 27440266
[TBL] [Abstract][Full Text] [Related]
9. High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.
Ludovini V; Bianconi F; Siggillino A; Vannucci J; Baglivo S; Berti V; Tofanetti FR; Reda MS; Bellezza G; Mandarano M; Belladonna ML; Metro G; Chiari R; Sidoni A; Puma F; Minotti V; Roila F
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671892
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.
Xiang Y; Liu X; Wang Y; Zheng D; Meng Q; Jiang L; Yang S; Zhang S; Zhang X; Liu Y; Wang B
Front Immunol; 2024; 15():1366260. PubMed ID: 38655260
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis.
Gianoncelli L; Spitaleri G; Passaro A; Radice D; Fumagalli C; Del Signore E; Stati V; Catania CM; Guerini-Rocco E; Barberis M; DE Marinis F
Anticancer Res; 2020 Jan; 40(1):427-433. PubMed ID: 31892597
[TBL] [Abstract][Full Text] [Related]
12. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer.
Chen Y; Chen Z; Chen R; Fang C; Zhang C; Ji M; Yang X
Future Oncol; 2022 May; 18(14):1757-1775. PubMed ID: 35232247
[TBL] [Abstract][Full Text] [Related]
14. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
15. Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice.
Faehling M; Kopp M; Schwenk B; Fallscheer S; Kramberg S; Eckert R
Oncology; 2019; 97(4):228-235. PubMed ID: 31216560
[TBL] [Abstract][Full Text] [Related]
16. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
17. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
18. Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review.
Li L; Xu F; Chen Y; Ren X; Liu Y; Chen Y; Xia S
BMJ Open; 2020 Nov; 10(11):e034010. PubMed ID: 33444168
[TBL] [Abstract][Full Text] [Related]
19. First-line immune-based combination therapies for advanced non-small cell lung cancer: A Bayesian network meta-analysis.
Mao Z; Jiang P; Zhang Y; Li Y; Jia X; Wang Q; Jiao M; Jiang L; Shen Y; Guo H
Cancer Med; 2021 Dec; 10(24):9139-9155. PubMed ID: 34747149
[TBL] [Abstract][Full Text] [Related]
20. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
